Loading clinical trials...
Loading clinical trials...
An Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Conditions
Interventions
Nivolumab
Ipilimumab
+1 more
Locations
1
United States
Medical University of South Carolina
Charleston, South Carolina, United States
Start Date
April 1, 2018
Primary Completion Date
April 1, 2018
Completion Date
April 1, 2018
Last Updated
June 18, 2018
NCT06391099
NCT06349642
NCT07300241
NCT05433142
NCT07227415
NCT06242470
Lead Sponsor
Medical University of South Carolina
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions